Revvity (RVTY) AI Stock Analysis

• Market Cap: $11.84B
• Dividend Yield: 0.29%
• Average Volume (3M): 1.03M
• Price to Earnings (P/E): 52.2
• Beta (1Y): 0.84
• Revenue Growth: 3.37%
• EPS Growth: -18.80%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.18
• Shares Outstanding: 113,375,620
• 10 Day Avg. Volume: 812,615
• 30 Day Avg. Volume: 1,033,510
• PEG Ratio: -0.13
• Price to Book (P/B): 1.78
• Price to Sales (P/S): 4.96
• P/FCF Ratio: 25.23
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 4.32
• Enterprise Value/Gross Profit: 8.35
• Enterprise Value/Ebitda: 15.77
• 1Y Price Target: $113.38
• Price Target Upside: 9.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: $114.00 ▲(9.73% Upside)

The score is driven by solid technical momentum and a constructive earnings outlook (raised EPS guidance, margin delivery, strong capital returns), tempered by mixed underlying financial quality (profitability and cash flow pressures) and a demanding valuation (high P/E with minimal dividend support).

Positive Factors

Strong SaaS growth & retention

High organic growth in the Signals software business, combined with ARR >40% and net retention above 110%, indicates durable recurring revenue and strong customer stickiness. This supports predictable revenue, high lifetime value, and scalable margin leverage over the medium term.

High adjusted operating margins

A 26.1% adjusted operating margin provides a strong profitability baseline and shows operational discipline. With restructuring plans and guidance targeting ~28% baseline, sustainable margin expansion could fund reinvestment, support returns and absorb cyclical pressures over 2–6 months.

Strategic partnerships & AI positioning

Partnerships with leading institutions expand Revvity's product pipeline and strengthen commercial channels in diagnostics and genomics. Combined with AI product initiatives, these strategic ties enhance differentiation, accelerate adoption, and create durable addressable-market advantages.

Negative Factors

Weak cash generation trends

Negative FCF growth and low operating-cash-to-net-income conversion constrain internal funding for R&D, M&A, and shareholder returns. Even with one-time free cash flow, persistent cash-generation pressure reduces financial flexibility and raises execution risk over the medium term.

China diagnostics exposure

A >20% drop in China diagnostics tied to DRG volume shifts signals structural market headwinds in a major geography. Prolonged policy-driven volume declines can materially depress growth and margins and reduce geographic diversification for several quarters.

Compressed profitability & low ROE

Declining net margin and a low ROE indicate limited efficiency in converting revenue into shareholder returns. Persistently compressed profitability can limit reinvestment capacity, make capital allocation more challenging, and temper long-term return expectations.

Revvity Business Overview & Revenue Model

Company Description

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Revvity generates revenue primarily through a subscription-based model for its software products, which provides clients with ongoing access to its analytics and AI tools. Additionally, the company earns income from professional services, including implementation, training, and consulting, which help clients to effectively integrate and utilize its technologies. Revvity also benefits from strategic partnerships with major tech firms and industry leaders, which enhance its market reach and provide additional revenue opportunities through joint ventures and co-branded offerings. Furthermore, the company may explore revenue from licensing its technology to third-party developers and organizations, further diversifying its income streams.

Revvity Financial Statement Overview

Summary

Revvity presents a stable financial profile with steady margins and a solid balance sheet. While profitability and revenue growth are under pressure, the company maintains strong operational cash flows and a healthy equity base, offering a balanced financial outlook with manageable risks.

Income Statement

Revvity's income statement shows moderate performance with a positive Gross Profit Margin of 55.93% and a decent Net Profit Margin of 10.19% for TTM. However, the company is facing challenges in revenue growth, with a slight increase of 1.58% from the previous year. EBIT Margin is satisfactory at 13.58%, although EBITDA Margin has decreased to 25.68% from last year's 30.50%.

Balance Sheet

The balance sheet reveals a stable financial position with a Debt-to-Equity Ratio of 0.45, indicating manageable leverage. Return on Equity (ROE) is moderate at 3.77% for TTM, reflecting a decrease in profitability compared to previous years. The Equity Ratio stands at a robust 61.11%, suggesting strong financial stability.

Cash Flow

Cash flow from operations is healthy, with an Operating Cash Flow to Net Income Ratio of 2.07, indicating efficient conversion of income into cash. However, Free Cash Flow declined by 6.05% from the previous year, and the Free Cash Flow to Net Income Ratio is 1.78, suggesting room for improvement in cash generation relative to income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.81B	2.76B	2.75B	3.31B	3.83B	3.78B
Gross Profit	1.45B	1.32B	1.32B	1.76B	2.28B	1.99B
EBITDA	770.02M	840.25M	713.56M	1.18B	1.62B	1.20B
Net Income	238.35M	295.83M	-118.38M	569.18M	943.16M	728.10M
Balance Sheet
Total Assets	12.14B	12.39B	13.56B	14.13B	15.00B	7.96B
Cash, Cash Equivalents and Short-Term Investments	931.39M	1.16B	1.60B	454.36M	603.32M	402.04M
Total Debt	3.37B	3.33B	4.07B	4.60B	5.16B	2.22B
Total Liabilities	4.76B	4.73B	5.69B	6.75B	7.86B	4.22B
Stockholders Equity	7.38B	7.67B	7.87B	7.38B	7.14B	3.74B
Cash Flow
Free Cash Flow	497.48M	541.65M	9.90M	594.18M	1.32B	828.54M
Operating Cash Flow	575.28M	628.30M	91.27M	679.81M	1.41B	892.18M
Investing Cash Flow	-14.23M	776.16M	1.31B	-132.85M	-4.11B	-504.50M
Financing Cash Flow	-874.20M	-1.13B	-947.12M	-661.80M	2.94B	-202.87M

Revvity Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 103.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Positive. The current price of 103.89 is above the 20-day moving average (MA) of 99.18, above the 50-day MA of 97.88, and above the 200-day MA of 94.09, indicating a bullish trend. The MACD of 1.41 indicates Negative momentum. The RSI at 60.45 is Neutral, neither overbought nor oversold. The STOCH value of 68.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RVTY.

Revvity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QGEN	77 Outperform	$9.99B	24.75	11.29%	3.31%	5.32%	336.29%
EXAS	70 Outperform	$19.39B	-19.23	-34.54%	―	14.47%	-353.69%
RVTY	69 Neutral	$11.84B	52.22	3.04%	0.29%	3.37%	-18.80%
DGX	69 Neutral	$19.41B	20.47	13.69%	1.80%	13.74%	14.87%
ILMN	67 Neutral	$21.56B	32.61	31.20%	―	-2.39%	―
GH	58 Neutral	$14.25B	-33.48	―	―	30.38%	24.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Revvity Corporate Events

Revvity Raises 2025 Outlook With Strong Preliminary Results

On January 12, 2026, Revvity said it will report its fourth-quarter and full-year 2025 results before the market opens on February 2, 2026, followed by an earnings call led by CEO Prahlad Singh and CFO Max Krakowiak, and confirmed that Singh is scheduled to present at the J.P. Morgan Healthcare Conference on January 13, 2026. The company issued preliminary figures indicating fourth-quarter 2025 reported and organic revenue growth of about 6% and 4%, respectively, implying roughly $772 million in sales, and full-year 2025 reported and organic revenue growth of about 4% and 3%, respectively, for approximately $2.855 billion in revenue, while also indicating that adjusted earnings per share for 2025 are now expected to come in above the previously guided upper end of $5.00, signaling operational outperformance and a stronger earnings profile heading into 2026.

The most recent analyst rating on (RVTY) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Revvity stock, see the RVTY Stock Forecast page.

Revvity Appoints Anita Gonzales as Chief Accounting Officer

On October 23, 2025, Revvity, Inc. announced the appointment of Anita Gonzales as Vice President and Chief Accounting Officer. Gonzales, who has been with the company since March 2021, previously held roles at General Electric and PricewaterhouseCoopers, bringing extensive experience in audit and accounting to her new position.

The most recent analyst rating on (RVTY) stock is a Buy with a $122.00 price target. To see the full list of analyst forecasts on Revvity stock, see the RVTY Stock Forecast page.